Takeda UK have today announced the launch of Prostap® DCS, a leuprorelin acetate dual chamber pre-filled syringe. This new presentation of leuprorelin acetate is to treat prostate cancer in men and endometriosis and uterine fibroids in women. This treatment will be available in the UK at no extra cost to the NHS and will replace current presentations of Prostap® (Prostap® SR and Prostap® 3) by the end of October 2011.
The Prostap® DCS reduces device preparation time, giving healthcare professionals more patient-facing time. It is also the only LHRH agonist delivered via a dual Chamber pre-filled syringe, offering a more simple and efficient delivery system compared to the original Prostap® vial and syringe mechanism. Prostap® DCS offers the same active ingredient and dose choices as Prostap® and provides well-documented, long-term efficacy and survival outcomes in all stages of prostate cancer.
“Leuprorelin acetate has proved to be an efficacious treatment for prostate cancer for many years. An accurate and user-friendly delivery system can only be a positive step forward, particularly as administration is more efficient and therefore saves time. This can result in a better standard of care for patients as more time is spent providing much needed support and advice.” Said Mr Raj Persad, Consultant Urologist, Bristol Royal Infirmary and Southmead Hospital.